Radiation guidelines for gliomas

Gliomas are the most frequent primary brain tumour. The proximity of organs at risk, the infiltrating nature, and the radioresistance of gliomas have to be taken into account in the choice of prescribed dose and technique of radiotherapy. The management of glioma patients is based on clinical factor...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer radiothérapie 2022-02, Vol.26 (1-2), p.116-128
Hauptverfasser: Antoni, D., Feuvret, L., Biau, J., Robert, C., Mazeron, J.-J., Noël, G.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 128
container_issue 1-2
container_start_page 116
container_title Cancer radiothérapie
container_volume 26
creator Antoni, D.
Feuvret, L.
Biau, J.
Robert, C.
Mazeron, J.-J.
Noël, G.
description Gliomas are the most frequent primary brain tumour. The proximity of organs at risk, the infiltrating nature, and the radioresistance of gliomas have to be taken into account in the choice of prescribed dose and technique of radiotherapy. The management of glioma patients is based on clinical factors (age, KPS) and tumour characteristics (histology, molecular biology, tumour location), and strongly depends on available and associated treatments, such as surgery, radiation therapy, and chemotherapy. The knowledge of molecular biomarkers is currently essential, they are increasingly evolving as additional factors that facilitate diagnostics and therapeutic decision-making. We present the update of the recommendations of the French society for radiation oncology on the indications and the technical procedures for performing radiation therapy in patients with gliomas. Les gliomes sont les tumeurs cérébrales primitives de l’adulte les plus fréquentes. La proximité des organes à risque, leur nature infiltrante et leur faible radiosensibilité sont des facteurs à prendre en compte dans le choix des doses et techniques d’irradiation. La prise en charge des patients atteints de gliomes repose sur les caractéristiques cliniques du patient, et de la tumeur (histologie, biologie moléculaire, localisation anatomique), ainsi que sur la nature des traitements disponibles et associés. La connaissance des marqueurs moléculaires tumoraux est devenue essentielle ces dernières années. La multitude de facteurs a rendu complexe les stratégies thérapeutiques pour ces patients de pronostic très variable. Les radiations constituent toujours un pilier majeur du traitement des gliomes. Nous présentons la mise à jour des recommandations de la Société française de radiothérapie oncologique sur les indications et les modalités techniques de réalisation de la radiothérapie pour les patients atteints de gliome.
doi_str_mv 10.1016/j.canrad.2021.08.006
format Article
fullrecord <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03889553v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1278321821001955</els_id><sourcerecordid>2614753638</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-4a6130d5849bcbde64a8280bba3eac80f7acd1bd4f90490c31828e446e8cd6ee3</originalsourceid><addsrcrecordid>eNp9kE1LAzEQQIMotlb_gcge9bBrsslmk4sgRa1QEETPIZvM1pT9qMm24L83ZWuPnmaYeTPDPISuCc4IJvx-nRndeW2zHOckwyLDmJ-gKSm5TDkvxGnM81KkNCdigi5CWONIcFmcowllsqBciilK3rV1enB9l6y2zkLjOghJ3ftk1bi-1eESndW6CXB1iDP0-fz0MV-ky7eX1_njMjVU8iFlmhOKbSGYrExlgTMtcoGrSlPQRuC61MaSyrJaYiaxoSS2gTEOwlgOQGfobtz7pRu18a7V_kf12qnF41Lta5gKIYuC7khkb0d24_vvLYRBtS4YaBrdQb8NKueElfFBKiLKRtT4PgQP9XE3wWrvUa3V6FHtPSosVLQUx24OF7ZVC_Y49CcuAg8jANHJzoFXwTjoDFjnwQzK9u7_C79zfoO2</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2614753638</pqid></control><display><type>article</type><title>Radiation guidelines for gliomas</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Antoni, D. ; Feuvret, L. ; Biau, J. ; Robert, C. ; Mazeron, J.-J. ; Noël, G.</creator><creatorcontrib>Antoni, D. ; Feuvret, L. ; Biau, J. ; Robert, C. ; Mazeron, J.-J. ; Noël, G.</creatorcontrib><description>Gliomas are the most frequent primary brain tumour. The proximity of organs at risk, the infiltrating nature, and the radioresistance of gliomas have to be taken into account in the choice of prescribed dose and technique of radiotherapy. The management of glioma patients is based on clinical factors (age, KPS) and tumour characteristics (histology, molecular biology, tumour location), and strongly depends on available and associated treatments, such as surgery, radiation therapy, and chemotherapy. The knowledge of molecular biomarkers is currently essential, they are increasingly evolving as additional factors that facilitate diagnostics and therapeutic decision-making. We present the update of the recommendations of the French society for radiation oncology on the indications and the technical procedures for performing radiation therapy in patients with gliomas. Les gliomes sont les tumeurs cérébrales primitives de l’adulte les plus fréquentes. La proximité des organes à risque, leur nature infiltrante et leur faible radiosensibilité sont des facteurs à prendre en compte dans le choix des doses et techniques d’irradiation. La prise en charge des patients atteints de gliomes repose sur les caractéristiques cliniques du patient, et de la tumeur (histologie, biologie moléculaire, localisation anatomique), ainsi que sur la nature des traitements disponibles et associés. La connaissance des marqueurs moléculaires tumoraux est devenue essentielle ces dernières années. La multitude de facteurs a rendu complexe les stratégies thérapeutiques pour ces patients de pronostic très variable. Les radiations constituent toujours un pilier majeur du traitement des gliomes. Nous présentons la mise à jour des recommandations de la Société française de radiothérapie oncologique sur les indications et les modalités techniques de réalisation de la radiothérapie pour les patients atteints de gliome.</description><identifier>ISSN: 1278-3218</identifier><identifier>EISSN: 1769-6658</identifier><identifier>DOI: 10.1016/j.canrad.2021.08.006</identifier><identifier>PMID: 34953698</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Age Factors ; Aged ; Anaplastic glioma ; Antineoplastic Agents, Alkylating ; Antineoplastic Agents, Alkylating - therapeutic use ; Biologie moléculaire ; Biomarkers ; Biomarkers, Tumor ; Biomarkers, Tumor - genetics ; Brain Neoplasms ; Brain Neoplasms - diagnostic imaging ; Brain Neoplasms - genetics ; Brain Neoplasms - pathology ; Brain Neoplasms - radiotherapy ; Cancer ; Clinical Decision-Making ; Diffuse glioma ; France ; French society for radiation oncology ; Glioblastoma ; Glioblastoma - diagnostic imaging ; Glioblastoma - radiotherapy ; Glioblastome ; Glioma ; Glioma - diagnostic imaging ; Glioma - genetics ; Glioma - pathology ; Glioma - radiotherapy ; Gliome anaplasique ; Gliome diffus ; Humans ; Karnofsky Performance Status ; Life Sciences ; Magnetic Resonance Imaging ; Middle Aged ; Neoplasm Grading ; Organs at Risk ; Radiation Oncology ; Radiation therapy ; Radiation Tolerance ; Radiothérapie ; Recommandations ; Recommendations ; Societies, Medical ; Société française de radiothérapie oncologique ; Temozolomide ; Temozolomide - therapeutic use</subject><ispartof>Cancer radiothérapie, 2022-02, Vol.26 (1-2), p.116-128</ispartof><rights>2021 Société française de radiothérapie oncologique (SFRO)</rights><rights>Copyright © 2021 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-4a6130d5849bcbde64a8280bba3eac80f7acd1bd4f90490c31828e446e8cd6ee3</citedby><cites>FETCH-LOGICAL-c396t-4a6130d5849bcbde64a8280bba3eac80f7acd1bd4f90490c31828e446e8cd6ee3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.canrad.2021.08.006$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34953698$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-03889553$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Antoni, D.</creatorcontrib><creatorcontrib>Feuvret, L.</creatorcontrib><creatorcontrib>Biau, J.</creatorcontrib><creatorcontrib>Robert, C.</creatorcontrib><creatorcontrib>Mazeron, J.-J.</creatorcontrib><creatorcontrib>Noël, G.</creatorcontrib><title>Radiation guidelines for gliomas</title><title>Cancer radiothérapie</title><addtitle>Cancer Radiother</addtitle><description>Gliomas are the most frequent primary brain tumour. The proximity of organs at risk, the infiltrating nature, and the radioresistance of gliomas have to be taken into account in the choice of prescribed dose and technique of radiotherapy. The management of glioma patients is based on clinical factors (age, KPS) and tumour characteristics (histology, molecular biology, tumour location), and strongly depends on available and associated treatments, such as surgery, radiation therapy, and chemotherapy. The knowledge of molecular biomarkers is currently essential, they are increasingly evolving as additional factors that facilitate diagnostics and therapeutic decision-making. We present the update of the recommendations of the French society for radiation oncology on the indications and the technical procedures for performing radiation therapy in patients with gliomas. Les gliomes sont les tumeurs cérébrales primitives de l’adulte les plus fréquentes. La proximité des organes à risque, leur nature infiltrante et leur faible radiosensibilité sont des facteurs à prendre en compte dans le choix des doses et techniques d’irradiation. La prise en charge des patients atteints de gliomes repose sur les caractéristiques cliniques du patient, et de la tumeur (histologie, biologie moléculaire, localisation anatomique), ainsi que sur la nature des traitements disponibles et associés. La connaissance des marqueurs moléculaires tumoraux est devenue essentielle ces dernières années. La multitude de facteurs a rendu complexe les stratégies thérapeutiques pour ces patients de pronostic très variable. Les radiations constituent toujours un pilier majeur du traitement des gliomes. Nous présentons la mise à jour des recommandations de la Société française de radiothérapie oncologique sur les indications et les modalités techniques de réalisation de la radiothérapie pour les patients atteints de gliome.</description><subject>Age Factors</subject><subject>Aged</subject><subject>Anaplastic glioma</subject><subject>Antineoplastic Agents, Alkylating</subject><subject>Antineoplastic Agents, Alkylating - therapeutic use</subject><subject>Biologie moléculaire</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Brain Neoplasms</subject><subject>Brain Neoplasms - diagnostic imaging</subject><subject>Brain Neoplasms - genetics</subject><subject>Brain Neoplasms - pathology</subject><subject>Brain Neoplasms - radiotherapy</subject><subject>Cancer</subject><subject>Clinical Decision-Making</subject><subject>Diffuse glioma</subject><subject>France</subject><subject>French society for radiation oncology</subject><subject>Glioblastoma</subject><subject>Glioblastoma - diagnostic imaging</subject><subject>Glioblastoma - radiotherapy</subject><subject>Glioblastome</subject><subject>Glioma</subject><subject>Glioma - diagnostic imaging</subject><subject>Glioma - genetics</subject><subject>Glioma - pathology</subject><subject>Glioma - radiotherapy</subject><subject>Gliome anaplasique</subject><subject>Gliome diffus</subject><subject>Humans</subject><subject>Karnofsky Performance Status</subject><subject>Life Sciences</subject><subject>Magnetic Resonance Imaging</subject><subject>Middle Aged</subject><subject>Neoplasm Grading</subject><subject>Organs at Risk</subject><subject>Radiation Oncology</subject><subject>Radiation therapy</subject><subject>Radiation Tolerance</subject><subject>Radiothérapie</subject><subject>Recommandations</subject><subject>Recommendations</subject><subject>Societies, Medical</subject><subject>Société française de radiothérapie oncologique</subject><subject>Temozolomide</subject><subject>Temozolomide - therapeutic use</subject><issn>1278-3218</issn><issn>1769-6658</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LAzEQQIMotlb_gcge9bBrsslmk4sgRa1QEETPIZvM1pT9qMm24L83ZWuPnmaYeTPDPISuCc4IJvx-nRndeW2zHOckwyLDmJ-gKSm5TDkvxGnM81KkNCdigi5CWONIcFmcowllsqBciilK3rV1enB9l6y2zkLjOghJ3ftk1bi-1eESndW6CXB1iDP0-fz0MV-ky7eX1_njMjVU8iFlmhOKbSGYrExlgTMtcoGrSlPQRuC61MaSyrJaYiaxoSS2gTEOwlgOQGfobtz7pRu18a7V_kf12qnF41Lta5gKIYuC7khkb0d24_vvLYRBtS4YaBrdQb8NKueElfFBKiLKRtT4PgQP9XE3wWrvUa3V6FHtPSosVLQUx24OF7ZVC_Y49CcuAg8jANHJzoFXwTjoDFjnwQzK9u7_C79zfoO2</recordid><startdate>202202</startdate><enddate>202202</enddate><creator>Antoni, D.</creator><creator>Feuvret, L.</creator><creator>Biau, J.</creator><creator>Robert, C.</creator><creator>Mazeron, J.-J.</creator><creator>Noël, G.</creator><general>Elsevier Masson SAS</general><general>Elsevier Masson</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope></search><sort><creationdate>202202</creationdate><title>Radiation guidelines for gliomas</title><author>Antoni, D. ; Feuvret, L. ; Biau, J. ; Robert, C. ; Mazeron, J.-J. ; Noël, G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-4a6130d5849bcbde64a8280bba3eac80f7acd1bd4f90490c31828e446e8cd6ee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Age Factors</topic><topic>Aged</topic><topic>Anaplastic glioma</topic><topic>Antineoplastic Agents, Alkylating</topic><topic>Antineoplastic Agents, Alkylating - therapeutic use</topic><topic>Biologie moléculaire</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Brain Neoplasms</topic><topic>Brain Neoplasms - diagnostic imaging</topic><topic>Brain Neoplasms - genetics</topic><topic>Brain Neoplasms - pathology</topic><topic>Brain Neoplasms - radiotherapy</topic><topic>Cancer</topic><topic>Clinical Decision-Making</topic><topic>Diffuse glioma</topic><topic>France</topic><topic>French society for radiation oncology</topic><topic>Glioblastoma</topic><topic>Glioblastoma - diagnostic imaging</topic><topic>Glioblastoma - radiotherapy</topic><topic>Glioblastome</topic><topic>Glioma</topic><topic>Glioma - diagnostic imaging</topic><topic>Glioma - genetics</topic><topic>Glioma - pathology</topic><topic>Glioma - radiotherapy</topic><topic>Gliome anaplasique</topic><topic>Gliome diffus</topic><topic>Humans</topic><topic>Karnofsky Performance Status</topic><topic>Life Sciences</topic><topic>Magnetic Resonance Imaging</topic><topic>Middle Aged</topic><topic>Neoplasm Grading</topic><topic>Organs at Risk</topic><topic>Radiation Oncology</topic><topic>Radiation therapy</topic><topic>Radiation Tolerance</topic><topic>Radiothérapie</topic><topic>Recommandations</topic><topic>Recommendations</topic><topic>Societies, Medical</topic><topic>Société française de radiothérapie oncologique</topic><topic>Temozolomide</topic><topic>Temozolomide - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Antoni, D.</creatorcontrib><creatorcontrib>Feuvret, L.</creatorcontrib><creatorcontrib>Biau, J.</creatorcontrib><creatorcontrib>Robert, C.</creatorcontrib><creatorcontrib>Mazeron, J.-J.</creatorcontrib><creatorcontrib>Noël, G.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Cancer radiothérapie</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Antoni, D.</au><au>Feuvret, L.</au><au>Biau, J.</au><au>Robert, C.</au><au>Mazeron, J.-J.</au><au>Noël, G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Radiation guidelines for gliomas</atitle><jtitle>Cancer radiothérapie</jtitle><addtitle>Cancer Radiother</addtitle><date>2022-02</date><risdate>2022</risdate><volume>26</volume><issue>1-2</issue><spage>116</spage><epage>128</epage><pages>116-128</pages><issn>1278-3218</issn><eissn>1769-6658</eissn><abstract>Gliomas are the most frequent primary brain tumour. The proximity of organs at risk, the infiltrating nature, and the radioresistance of gliomas have to be taken into account in the choice of prescribed dose and technique of radiotherapy. The management of glioma patients is based on clinical factors (age, KPS) and tumour characteristics (histology, molecular biology, tumour location), and strongly depends on available and associated treatments, such as surgery, radiation therapy, and chemotherapy. The knowledge of molecular biomarkers is currently essential, they are increasingly evolving as additional factors that facilitate diagnostics and therapeutic decision-making. We present the update of the recommendations of the French society for radiation oncology on the indications and the technical procedures for performing radiation therapy in patients with gliomas. Les gliomes sont les tumeurs cérébrales primitives de l’adulte les plus fréquentes. La proximité des organes à risque, leur nature infiltrante et leur faible radiosensibilité sont des facteurs à prendre en compte dans le choix des doses et techniques d’irradiation. La prise en charge des patients atteints de gliomes repose sur les caractéristiques cliniques du patient, et de la tumeur (histologie, biologie moléculaire, localisation anatomique), ainsi que sur la nature des traitements disponibles et associés. La connaissance des marqueurs moléculaires tumoraux est devenue essentielle ces dernières années. La multitude de facteurs a rendu complexe les stratégies thérapeutiques pour ces patients de pronostic très variable. Les radiations constituent toujours un pilier majeur du traitement des gliomes. Nous présentons la mise à jour des recommandations de la Société française de radiothérapie oncologique sur les indications et les modalités techniques de réalisation de la radiothérapie pour les patients atteints de gliome.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>34953698</pmid><doi>10.1016/j.canrad.2021.08.006</doi><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1278-3218
ispartof Cancer radiothérapie, 2022-02, Vol.26 (1-2), p.116-128
issn 1278-3218
1769-6658
language eng
recordid cdi_hal_primary_oai_HAL_hal_03889553v1
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Age Factors
Aged
Anaplastic glioma
Antineoplastic Agents, Alkylating
Antineoplastic Agents, Alkylating - therapeutic use
Biologie moléculaire
Biomarkers
Biomarkers, Tumor
Biomarkers, Tumor - genetics
Brain Neoplasms
Brain Neoplasms - diagnostic imaging
Brain Neoplasms - genetics
Brain Neoplasms - pathology
Brain Neoplasms - radiotherapy
Cancer
Clinical Decision-Making
Diffuse glioma
France
French society for radiation oncology
Glioblastoma
Glioblastoma - diagnostic imaging
Glioblastoma - radiotherapy
Glioblastome
Glioma
Glioma - diagnostic imaging
Glioma - genetics
Glioma - pathology
Glioma - radiotherapy
Gliome anaplasique
Gliome diffus
Humans
Karnofsky Performance Status
Life Sciences
Magnetic Resonance Imaging
Middle Aged
Neoplasm Grading
Organs at Risk
Radiation Oncology
Radiation therapy
Radiation Tolerance
Radiothérapie
Recommandations
Recommendations
Societies, Medical
Société française de radiothérapie oncologique
Temozolomide
Temozolomide - therapeutic use
title Radiation guidelines for gliomas
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T21%3A29%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Radiation%20guidelines%20for%20gliomas&rft.jtitle=Cancer%20radioth%C3%A9rapie&rft.au=Antoni,%20D.&rft.date=2022-02&rft.volume=26&rft.issue=1-2&rft.spage=116&rft.epage=128&rft.pages=116-128&rft.issn=1278-3218&rft.eissn=1769-6658&rft_id=info:doi/10.1016/j.canrad.2021.08.006&rft_dat=%3Cproquest_hal_p%3E2614753638%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2614753638&rft_id=info:pmid/34953698&rft_els_id=S1278321821001955&rfr_iscdi=true